AI is rapidly rewriting the rules for drug discovery and clinical trials. As highlighted in the latest Research and Markets report:

🧬 By 2025, 30% of new drugs will be discovered using AI, a seismic shift from traditional methods.

⏳ AI-enabled workflows can cut the time to preclinical candidate selection by up to 40% and reduce costs by 30%—a game-changer in an industry where bringing a new drug to market can take 14.6 years and $2.6 billion.

📈 The global AI in drug discovery market is booming: from $1.72 billion in 2024 to a projected $8.53 billion by 2030, growing at an impressive CAGR of 30.59%

This momentum is fueled by technological innovation, expanding data, rising R&D costs, and the urgent need for solutions to chronic diseases.

At Clinakos Inc., our Integrated Patient Data™ platform brings together real-world, clinical, and omics data, delivering the depth and fidelity the industry now demands. Paired with our Medically Smart AI™, which leverages advanced machine learning and natural language processing, we help uncover insights, optimize trial design, and accelerate drug development—exactly in line with the trends spotlighted in the report.

Ready to experience the Clinakos advantage? 📅 Book a time with our team [https://lnkd.in/gp3gUmXc]

👉Follow us at Clinakos Inc. 

👉Read the full article here